4 results about "Marker vaccine" patented technology

The present disclosure provides an N protein epitope mutation marker for preparing an epitope deletion-marked vaccine strain of type II porcine reproductive and respiratory syndrome virus (PRRSV) and use thereof, belonging to the technical field of biological products. In the mutation marker, one or more amino acids are mutated based on an epitope sequence at positions 92 to 103 of a C-terminal of an N protein of the type II PRRSV; and the epitope mutation marker has an amino acid sequence shown in SEQ ID NO: 1, where X1 is selected from the group consisting of T, P, and A; and X2 is selected from the group consisting of V and A.

The invention discloses a dual TaqMan real-time fluorescent quantitative PCR (Polymerase Chain Reaction) detection method for zonal Brucella wild strain infection and an A19 delta bpe275 labeled vaccine strain. The dual TaqMan real-time fluorescent quantitative PCR detection method comprises the following steps: extracting nucleic acid of a sample to be detected; the extracted nucleic acid is taken as a template, fluorescent quantitative PCR amplification is simultaneously carried out in the same reaction system, and the reaction system comprises a first primer probe combination for detecting the bpe275 gene, collecting fluorescent signals of the first fluorescent reporter group and the second fluorescent reporter group, and interpreting the detection result according to the amplification condition of the fluorescent signals. According to the present invention, the non-specific amplification risk is significantly reduced by using the specific primer and probe combination aiming at the bpe275 and bab11216 genes, the accuracy and the reliability of the detection result are ensured, the dual-target detection can be completed in the one-time reaction by using the dual-fluorescence real-time quantitative PCR technology, the detection efficiency is significantly improved, and the kit is suitable for the large-batch sample detection.

The present invention relates to immunogen carriers, wherein said immunogen carriers are preferably virus-like particles (VLPs) comprising a plurality of modified PCV2 ORF2 proteins. In particular, the present invention belongs to the field of compliance markers and marker vaccines allowing to distinguish between infected and vaccinated individuals. In particular, it relates to compliance markers for vaccines comprising subunit antigens and DIVA (distinguishing infected from vaccinated animals) systems, which enable to distinguish between animals infected with a pathogen and animals treated with subunit antigens derived from said pathogen.

The application belongs to the technical field of biology and relates to a broad-spectrum monoclonal antibody for recognizing a linear antigen epitope at the C-terminal of foot-and-mouth disease virus VP2 protein and application thereof. The monoclonal antibody pOTB-1 is successfully constructed, the amino acid sequence of the heavy chain variable region is as shown in SEQ ID No. 6, and the amino acid sequence of the light chain variable region is as shown in SEQ ID No. 7. The biological activity of the antibody is verified by indirect immunofluorescence test, enzyme-linked immunosorbent assay and Western-blot. The antibody exhibits broad-spectrum reactivity to O type and A type FMDV and has strong binding affinity. The antibody recognizes a continuous linear B cell epitope at the C-terminal of the structural protein VP2. The epitope sequence is highly conserved among FMDV O type, A type and Asia1 type, which indicates that there is an inter-type common antigen site in the capsid protein VP2. A competitive ELISA detection method is established based on biotinylated pOTB-1, which provides a tool for the prevention and control of FMDV and serological detection, and lays a foundation for the design of FMDV marker vaccine and the evaluation of immunization effect.